WO2008122966A2 - A pharmaceutical composition of tacrolimus - Google Patents

A pharmaceutical composition of tacrolimus Download PDF

Info

Publication number
WO2008122966A2
WO2008122966A2 PCT/IE2008/000039 IE2008000039W WO2008122966A2 WO 2008122966 A2 WO2008122966 A2 WO 2008122966A2 IE 2008000039 W IE2008000039 W IE 2008000039W WO 2008122966 A2 WO2008122966 A2 WO 2008122966A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
tacrolimus
minicapsules
release
released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2008/000039
Other languages
English (en)
French (fr)
Other versions
WO2008122966A3 (en
Inventor
Ivan Coulter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigmoid Pharma Ltd
Original Assignee
Sigmoid Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmoid Pharma Ltd filed Critical Sigmoid Pharma Ltd
Priority to US12/594,553 priority Critical patent/US8911777B2/en
Priority to CA002683409A priority patent/CA2683409A1/en
Priority to EP08719897A priority patent/EP2061440A2/en
Priority to JP2010501661A priority patent/JP2010523554A/ja
Priority to CN200880016191A priority patent/CN101677964A/zh
Publication of WO2008122966A2 publication Critical patent/WO2008122966A2/en
Publication of WO2008122966A3 publication Critical patent/WO2008122966A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Definitions

  • the present invention relates to pharmaceutical compositions comprising Tacrolimus.
  • Tacrolimus a macrolide agent, inhibits T-lymphocyte activation through a process that is thought to involve it binding to an intracellular protein, FKBP- 12.
  • a hydrophobic complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited.
  • This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon).
  • NF-AT nuclear factor of activated T-cells
  • lymphokines such as interleukin-2, gamma interferon
  • Tacrolimus is primarily used in post-organ transplant patients to prevent organ rejection.
  • the tacrolimus dose is adjusted to maintain whole blood trough concentrations of tacrolimus within the target range (10-20 ng/ml during the first 3 months and 5-15 ng/ml thereafter (Yasuhara et al., (1995) Transplantation Proceedings, 27, 1 108-1 1 10).
  • Tacrolimus is differentially absorbed from in different regions of the gastrointestinal tract, being optimally absorbed from the small intestine, with ileum and colonic absorption efficiency dropping to half that observed for the small intestine. Also, a food effect is observed. After absorption from the gastrointestinal tract, drug effects persist for 8-12 hours after oral administration of conventional IR tablets. The total dosage is typically in the range of 2.5-10 mg per day, in exceptional cases rising to 20 mg/day.
  • Tacrolimus is given twice daily, typically with one dose given before breakfast and a second dose given in the late afternoon.
  • Adverse effects due to the initial rapid absorption from the small intestine results in above therapeutic plasma concentrations, associated with tacrolimus treatment include nephrotoxicity, neurotoxicity and the development of patient infection due to immunosuppression.
  • a once-daily formulation of tacrolimus is known.
  • the formulation process consists of tacrolimus being granulated with dehydrated ethanol, ethylcellulose, hypromellose and lactose monohydrate.
  • the hypromellose system modifies the drug release profile by forming a polymer gel layer and the ethylcellulose diffusion matrix system modifies the release profile by controlling water penetration and thus drug release.
  • the resulting paste undergoes drying and sizing to produce intermediate granules.
  • the granules are then mixed with lactose monohydrate and magnesium stearate and that mixture is filled into capsules.
  • the formulation results in dissolution of 90% drug release at 6 to 12 hours.
  • One potential problem with this once-daily product results in an initial spike in the drug plasma concentration, with the potential to cause unwanted side effects.
  • an oral tacrolimus composition comprising minicapsules having a core containing tacrolimus in a solubilised liquid form, the minicapsules having a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract.
  • the minicapsules have a release profile to release pre-solubilised tacrolimus in the small intestine.
  • the minicapsules have a release profile to release pre-solubilised tacrolimus in the ileum.
  • the minicapsules have a release profile to release pre-solubilised tacrolimus in the colon.
  • tacrolimus is present in the core in an amount of from 0.5 to 25% w/w, preferably in an amount of from 2.5 to 15% w/w.
  • the tacrolimus when exposed to a use environment less than or equal to 100% of the tacrolimus is released within 24 hours. In one embodiment when exposed to a use environment less than 20% of the tacrolimus is released within 1 hour, less than 35% of the tacrolimus is released within 4 hours, less than 65% of the tacrolimus is released within 12 hours, and substantially all of the remaining tacrolimus is released between 12 and 24 hours.
  • the minicapsules may comprise a solid shell containing the solubilised tacrolimus.
  • the minicapsules may be modified to provide the release profile.
  • a modified release may be attributable to a polymer coating.
  • the polymeric material may, for example, be a methacrylate, or ethylcellulose.
  • the polymeric material may be a composite of methacrylate and ethylcellulose.
  • the coating includes a dissolution enhancing agent.
  • the dissolution enhancing agent may be degraded by bacteria normally present in the gastrointestinal tract.
  • the dissolution enhancing agent may be selected from one or more of pectin, amylose and alginate.
  • the dissolution enhancing agent can be present in an amount of from 0.5 to 2% w/w of ethylcellulose.
  • the core comprises tacrolimus, a solubilisation agent, a co-emulsifier, a surfactant, a permeability enhancer and a carrier.
  • the solubilisation agent may comprise ethanol.
  • the solubilisation agent may comprise triglycerides.
  • the co- emulsifying agent may comprise fatty acid ester complexes.
  • the surfactant agent may comprise fatty acid ester complexes.
  • the permeability enhancing agent may comprise fatty acid ester complexes.
  • the carrier may comprise a hydrophobic liquid.
  • the hydrophobic liquid may comprise an oil such as olive oil.
  • the composition comprises a first population of minicapsules comprising tacrolimus and a second population of minicapsules comprising tacrolimus.
  • the first population may comprise uncoated minicapsules.
  • the second population may comprise coated minicapsules.
  • the composition comprises from 10 to 40% w/w uncoated minicapsules and from 60 to 90% w/w coated minicapsules.
  • tacrolimus is released along the gastrointestinal tract in a form that maximises systemic absorption.
  • the tacrolimus may be released along the gastrointestinal tract in a form that maximises pre-systemic mucosal absorption.
  • the tacrolimus may be released along the gastrointestinal tract in a form that maximises local gastrointestinal activity.
  • Tacrolimus may be released along the gastrointestinal tract in a form that maximises chronotherapy.
  • the formulation contains an adhesive entity such as a muco- or bio- adhesive.
  • the minicapsules may be administered in a hard gelatine capsule, a sprinkle, or a tablet.
  • the minicapsules further comprise excipients to maximise the solubility of tacrolimus.
  • the composition may comprise excipients to maximise permeability of tacrolimus in the ileum.
  • the ileum permeability enhancing excipients may be selected from one or more of: - sodium caprate, sodium dodecanoate, sodium palmitate, SNAC, chitosan and derivatives thereof, fatty acids, surfactants, liposomes, triglycerides, polyethers, bile salts, nitric oxide donors, triglycerides, hydroxylase inhibitors and/or antioxidants.
  • the composition comprises excipients to maximise permeability of tacrolimus in the colon.
  • the colon permeability enhancing excipients may be selected from one or more of: - sodium caprate, sodium dodecanoate, sodium palmitate, SNAC, chitosan and derivatives thereof, fatty acids, surfactants, liposomes, triglycerides, polyethers, bile salts, nitric oxide donors, triglycerides, hydroxylase inhibitors and/or antioxidants.
  • the composition may comprise excipients to enhance the therapeutic potential of tacrolimus in the ileum and colon.
  • the excipients may be selected from one or more of absorption limiters, absorption enhancers, surfactants, co-surfactants, co- solvents, essential oils such as omega 3 oils, natural plant extracts such as neem, ion-exchange resins, bacteria degradable conjugation linkers such as azo bonds, polysaccharides such as amylose, guar gum, pectin, chitosan, inulin and cyclodextrins.
  • the composition comprises excipients to enhance systemic bioavailability of tacrolimus following absorption throughout the gastrointestinal tract.
  • the excipients to enhance systemic bioavailability of tacrolimus following absorption in the small intestine may comprise efflux pump inhibitors, including,
  • PgP pump inhibitors and metabolism inhibitors, including, cytochrome P450 3A inhibitors.
  • the composition may also comprise excipients to reduce systemic side effects associated with absorption of tacrolimus in the small intestine.
  • the excipients to reduce systemic side effects associated with absorption of tacrolimus in the small intestine may comprise, antioxidants, such as curcuminoids, flavanoids or more specifically including curcumin, beta-carotene, ⁇ -tocopherol, ascorbate or lazaroid.
  • the composition facilitates absorption over 24 hours.
  • the composition may be used for the treatment or prevention of solid organ transplant rejection; for the treatment or prevention of graft-versus-host disease; for the treatment or prevention of gastro-intestinal graft-versus-host disease; in treating or preventing inflammatory bowel disease; in treating or preventing ulcerative colitis; in treating or preventing Crohn's disease.
  • composition may be combined with another active pharmaceutical ingredient in a single oral dosage form.
  • Fig. 1 is a graph showing the dissolution profile for uncoated tacrolimus minicapsules
  • Fig. 2 is a graph showing the dissolution profile for tacrolimus minicapsules coated with 12.5% EudragitTM RS30D followed by 25% EudragitTM FS30D;
  • Fig. 3 is a graph showing the dissolution profile for composite tacrolimus minicapsules - 30% uncoated (immediate release) and 70% coated with 12.5% EudragitTM RS30D followed by 25% EudragitTM FS30D;
  • Fig. 4 is a graph showin the dissolution profile for 15% weight gain EudragitTM profile for 15% weight gain EudragitTM RS30D - coated tacrolimus minicapsules;
  • Fig. 5 is a graph showing the dissolution profile for 15% weight gain EudragitTM RS30D / 25% weight gain Surlease® - coated tacrolimus minicapsules;
  • Fig. 6 is a graph showing the dissolution profile for 15% weight gain variable RS/RL coatings.
  • Fig. 7 is a schematic illustration of a liquid filled minicapsule of the type used in the formulations of the invention.
  • the invention provides a once-daily formulation of tacrolimus.
  • the composition provides a controlled release of a therapeutically effective amount of tacrolimus in combination with a pharmaceutically acceptable carrier(s) or excipient(s).
  • the resulting 24-hour controlled release will enable an improved pharmacokinetic profile leading to a potentially more effective, safer and convenient product.
  • the controlled release of active pharmaceutical agents is only truly useful if the agent is available to interact with its receptor or site of action in an active form. Unless the agent is in a fully soluble form it is unlikely to interact with its intended receptor or exert its desired action.
  • the invention is a drug delivery format that enables the release of tacrolimus from the format in soluble or readily-soluble form.
  • the invention permits the release of tacrolimus in soluble or readily-soluble for, it thus enables a true once-daily drug formulation, especially for a small molecule drug with poor water-solubility, possibly with limited stability or a short half-life such as tacrolimus, as the drug is absorbed not only in the small intestine but also in the colon.
  • the invention provides an oral drug delivery technology that permits throughout the entire gastrointestinal tract the release of pre- or readily-solubilised drugs in tandem with a controlled release formulation that permits release and absorption in the small intestine, ileum and/or colon of soluble tacrolimus to ensure true once-daily formulations which is an hydrophobic agent that has demonstrated variable bioavailability.
  • a colon-specific release formulation is advantageous as an effective drug delivery mechanism for the enhanced treatment of diseases of colon (including, but not limited to, ulcerative colitis, Chron's disease, Gastro- Intestinal Graft Versus Host Disease (GI-GVHD), Irritable Bowel Syndrome) whereby high local concentration can be achieved while minimizing side effects that occur because of release of drugs in the upper GIT or unnecessary systemic absorption.
  • diseases of colon including, but not limited to, ulcerative colitis, Chron's disease, Gastro- Intestinal Graft Versus Host Disease (GI-GVHD), Irritable Bowel Syndrome
  • Pulsatile release formats have proven successful for a range of drugs but many others have not benefited from such delivery systems and it has not been particularly successful for colon-specific or the development of true once-daily forms of certain drug classes, including low solubility small molecules and biopharmaceuticals.
  • Tacrolimus is an example of a drug that has demonstrated limited colonic absorption.
  • tacrolimus examples have proven difficult to formulate, true once- daily formats have proven difficult to develop.
  • enhanced delivery systems with the potential to combine aspects of any of solubility, permeability and stability enhancement along with gastro-intestinal targeted release are required.
  • a sustained release format of pre- solubilised Tacrolimus, exhibiting limited systemic absorption is desirable.
  • tacrolimus blocks T-cell activation, a prerequisite for HIV proliferation, it may be useful as a prophylactic for the prevention of HIV replication.
  • inhibition of T-cell mitosis would suppress the replication of the virus, since the virus relies upon the host T-cell's proliferative functions to replicate.
  • the formulations in the invention would be useful when used alone, or in combination therapy with other immunosuppressants and anti-retroviral agents, for example, but not limited to, cyclosporine, rapamycin, picibanil, mycophenolic acid, azathioprine, prednisolone, cyclophosphamide, brequinar, sequinivir and leflunomide as a prophylactic for the prevention of HlV replication which is rapid in the gastrointestinal tract following infection.
  • immunosuppressants and anti-retroviral agents for example, but not limited to, cyclosporine, rapamycin, picibanil, mycophenolic acid, azathioprine, prednisolone, cyclophosphamide, brequinar, sequinivir and leflunomide as a prophylactic for the prevention of HlV replication which is rapid in the gastrointestinal tract following infection.
  • anti-retroviral agents for example, but not limited to,
  • the tacrolimus formulations are useful when administered for the prevention of immune-mediated tissue or organ graft rejection.
  • transplanted tissues and organs which suffer from these effects are heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum ***, limb, muscle, nervus, duodenum, small-bowel, pancreatic-islet-cell, and the like; as well as graft-versus-host diseases brought about by medulla ossium transplantation.
  • the regulation of the immune response by the formulations of the invention would also find utility in the treatment of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosis, hyperimmunoglobulin E, Hashimoto's thyroiditis, multiple sclerosis, progressive systemic sclerosis, myasthenia gravis, type 1 diabetes, uveitis, allergic encephalomyelitis, glomerulonephritis, and the like; and further infectious diseases caused by pathogenic microorganisms, such as HlV (Human Immunodeficiency Virus).
  • autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis, hyperimmunoglobulin E, Hashimoto's thyroiditis, multiple sclerosis, progressive systemic sclerosis, myasthenia gravis, type 1 diabetes, uveitis, allergic encephalomyelitis, glomerulonephritis, and the like
  • Further uses for the current invention formulations include the treatment and prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses, such as psoriasis, atopic dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus, bullous pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus , acne and Alopecia areata; various eye diseases (autoimmune and otherwise) such as keratoconjunctivitis, vernal conjunctivitis, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, o
  • ischemic bowel diseases necrotizing enterocolitis, intestinal lesions associated with thermal burns and leukotriene B 4 -mediated diseases; intestinal inflammations/allergies such as Coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis; food-related allergic diseases which have symptomatic manifestation remote from the gastro-intestinal tract (e.g., migraine, rhinitis and eczema); renal diseases such as interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome and diabetic nephropathy; nervous diseases such as multiple myositis, Guillain-Barre-syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis and radiculopathy; endocrine diseases such as hyperthyroidism and Basedow's disease; hematic diseases such as pure red
  • the formulations of the invention are useful for the treatment and prevention of hepatic disease such as immunogenic diseases (for example, chronic autoimmune liver diseases such as the group consisting of autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g., necrosis caused by toxin, viral hepatitis, shock or anoxia), B-virus hepatitis, non-A/non-B hepatitis, cirrhosis (such as alcoholic cirrhosis) and hepatic failure such as fulminant hepatic failure, late-onset hepatic failure and "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases), and moreover are useful for various diseases because of their useful activity such as augmention of chemotherapeutic effect, preventing or treating activity of cytonegalovirus infection, particularly HCMV (Hu
  • the formulations of the invention may be used as vaccines to treat immunosuppression in a subject. It is sometimes found that the antigen introduced into the body for the acquisition of immunity from disease also acts as an immunosuppressive agent, and therefore, antibodies are not produced by the body and immunity is not acquired. By introducing a formulation of the invention into the body as a vaccine, the undesired immunosuppression may be overcome and immunity acquired.
  • the formulations of the invention may also find utility in the chemosensitization of drug resistant target cells.
  • Tacrolimus is known to be effective modulators of P-glycoprotein, a substance which binds to and inhibits the action of anticancer drugs by inhibiting P- glycoprotein, as they are capable of increasing the sensitivity of multidrug resistant (MDR) cells to chemotherapeutic agents.
  • MDR multidrug resistant
  • the formulations of the invention may likewise be effective at overcoming resistance expressed to clinically useful antitumour drugs such as 5-fluorouracil, cisplatin, methotrexate, vincristine, vinblastine and adriamycin. colchicine and vincristine.
  • Liquid dosage forms for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, the LabrafilTM range, LabrafracTM range, GelucireTM range, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, fish, neem and sesame oils), polyethers (in particular substances like dimethyl isosorbide, dimethyl isoodide and dimethly is
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Liquid formulations may contain, in addition to the active compounds, suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • Coating materials may include any combination of the commercially available acrylic-, methacrylic-, ethylcellulose-based polymers (such as, but not limited to the EudragitTM and Surelease® range), as well as other polymers with natural polysaccharides, including, but not limited to amylose, pectin, alginate, amylopectin, chitosan, galactomannan, guar gum and any derivatives thereof, has the potential to customise how, where and when drugs are released from the underlying or embedded solid, semi-solid or liquid forms.
  • any specific polymer may be interchanged or combined with any other polymer to enable the required release profile according to the preferred optimal therapeutic outcome envisaged.
  • the polymeric material comprises methacrylic acid co-polymers, ammonio methacrylate co-polymers, or mixtures thereof.
  • Methacrylic acid co-polymers such as EUDRAGITTM S and EUDRAGITTM L (Evonik) are suitable for use in the controlled release formulations of the present invention. These polymers are gastroresistant and enterosoluble polymers. Their polymer films are insoluble in pure water and diluted acids. They dissolve at higher pHs, depending on their content of carboxylic acid. EUDRAGITTM S and EUDRAGITTM L can be used as single components in the polymer coating or in combination in any ratio.
  • the polymeric material can exhibit solubility at a pH between the pHs at which EUDRAGITTM L and EUDRAGITTM S are separately soluble.
  • the membrane coating can comprise a polymeric material comprising a major proportion (i.e., greater than 50% of the total polymeric content) of at least one pharmaceutically acceptable water-soluble polymers, and optionally a minor proportion (i.e., less than 50% of the total polymeric content) of at least one pharmaceutically acceptable water insoluble polymers.
  • the membrane coating can comprise a polymeric material comprising a major proportion (i.e., greater than 50% of the total polymeric content) of at least one pharmaceutically acceptable water insoluble polymers, and optionally a minor proportion (i.e., less than 50% of the total polymeric content) of at least one pharmaceutically acceptable water-soluble polymer.
  • Ammonio methacrylate co-polymers such as EUDRAGITTM RS and EUDRAGITTM RL (Evonik) are suitable for use in the modified release formulations of the present invention. These polymers are insoluble in pure water, dilute acids, buffer solutions, or digestive fluids over the entire physiological pH range. The polymers swell in water and digestive fluids independently of pH. In the swollen state, they are then permeable to water and dissolved active agents. The permeability of the polymers depends on the ratio of ethylacrylate (EA), methyl methacrylate (MMA), and trimethylammonioethyl methacrylate chloride (TAMCl) groups in the polymer.
  • EA ethylacrylate
  • MMA methyl methacrylate
  • TAMCl trimethylammonioethyl methacrylate chloride
  • EUDRAGITTM RL Those polymers having EA:MMA:TAMC1 ratios of 1 :2:0.2 (EUDRAGITTM RL) are more permeable than those with ratios of 1 :2:0.1 (EUDRAGITTM RS).
  • Polymers of EUDRAGITTM RL are insoluble polymers of high permeability.
  • Polymers of EUDRAGITTM RS are insoluble films of low permeability.
  • the amino methacrylate co-polymers can be combined in any desired ratio, and the ratio can be modified to modify the rate of drug release.
  • a ratio of EUDRAGITTM RS: EUDRAGITTM RL of 90: 10 can be used.
  • the ratio of EUDRAGITTM RS: EUDRAGITTM RL can be about 100:0 to about 80:20, or about 100:0 to about 90:10, or any ratio in between.
  • the less permeable polymer EUDRAGITTM RS would generally comprise the majority of the polymeric material with the more soluble RL, when it dissolves, permitting creating gaps through which solutes can enter the core and dissolved pharmaceutical actives escape in a controlled manner.
  • the amino methacrylate co-polymers can be combined with the methacrylic acid co- polymers within the polymeric material in order to achieve the desired delay in the release of the drug. Ratios of ammonio methacrylate co-polymer (e.g., EUDRAGITTM RS) to methacrylic acid co-polymer in the range of about 99: 1 to about 20:80 can be used.
  • the two types of polymers can also be combined into the same polymeric material, or provided as separate coats that are applied to the core.
  • EudragitTM FS 30 D is an anionic aqueous-based acrylic polymeric dispersion consisting of methacrylic acid, methyl acrylate, and methyl methacrylate and is pH sensitive. This polymer contains fewer carboxyl groups and thus dissolves at a higher pH (> 6.5). The advantage of such a system is that it can be easily manufactured on a large scale in a reasonable processing time using conventional powder layering and fluidized bed coating techniques.
  • Eudragit FS 30 D demonstrated its potential for colonic delivery by resisting drug release up to pH 6.5 and the combination of EudragitTM RL and RS proved successful for the sustained delivery of 5-ASA at the pH of the colon.
  • EudragitTM FS 30 D alone or with other controlled release polymers holds great potential to enable delivery of minicapsule formulations specifically to the colon.
  • EUDRAGITTM polymers In addition to the EUDRAGITTM polymers described above, a number of other such copolymers can be used to control drug release. These include methacrylate ester co- polymers such as the EUDRAGITTM NE and EUDRAGITTM NM ranges. Further information on the EUDRAGITTM polymers can be found in "Chemistry and Application Properties of Polymethacrylate Coating Systems," in Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, ed. James McGinity, Marcel Dekker Inc., New York, pg 109-1 14. Several derivatives of hydroxypropyl methylcellulose (HPMC) also exhibit pH dependent solubility. Shin-Etsu Chemical Co., Ltd.
  • HPMC hydroxypropyl methylcellulose
  • HPMCP hydroxypropyl methylcellulose phthalate
  • HPMCAS hydroxypropyl methylcellulose acetate succinate
  • Surelease® dispersion is a unique combination of film-forming polymer; plasticizer and stabilizers. Designed for sustained release and taste masking applications, Surelease is an easy-to-use, totally aqueous coating system using ethylcellulose as the release rate controlling polymer. The dispersion provides the flexibility to adjust drug release rates with reproducible profiles that are relatively insensitive to pH. The principal means of drug release is by diffusion through the Surelease dispersion membrane and is directly controlled by film thickness. Increasing or decreasing the quantity of Surelease® applied can easily modify the rate of release. With Surelease dispersion, reproducible drug release profiles are consistent right through from development to scale-up and production processes.
  • polymers can include phthalate, butyrate, succinate, and/or mellitate groups.
  • Such polymers include, but are not limited to, cellulose acetate phthalate, cellulose acetate succinate, cellulose hydrogen phthalate, cellulose acetate trimellitate, hydroxypropyl-methylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, starch acetate phthalate, amylose acetate phthalate, polyvinyl acetate phthalate, and polyvinyl butyrate phthalate.
  • any combination of polymer may be blended to provide additional controlled- or targeted-release profiles.
  • the coating membrane can further comprise at least one soluble excipient to increase the permeability of the polymeric material.
  • the at least one soluble excipient is selected from among a soluble polymer, a surfactant, an alkali metal salt, an organic acid, a sugar, and a sugar alcohol.
  • Such soluble excipients include, but are not limited to, polyvinyl pyrrolidone, polyethylene glycol, sodium chloride, surfactants such as sodium lauryl sulfate and polysorbates, organic acids such as acetic acid, adipic acid, citric acid, fumaric acid, glutaric acid, malic acid, succinic acid, and tartaric acid, sugars such as dextrose, fructose, glucose, lactose, and sucrose, sugar alcohols such as lactitol, maltitol, mannitol, sorbitol, and xylitol, xanthan gum, dextrins, and maltodextrins.
  • polyvinyl pyrrolidone polyethylene glycol, sodium chloride
  • surfactants such as sodium lauryl sulfate and polysorbates
  • organic acids such as acetic acid, adipic acid, citric acid, fumaric acid, glutaric acid, malic
  • polyvinyl pyrrolidone, mannitol, and/or polyethylene glycol can be used as soluble excipients.
  • the at least one soluble excipient can be used in an amount ranging from about 1% to about 10% by weight, based on the total dry weight of the polymer.
  • the coating process can be carried out by any suitable means, for example, by using a perforated pan system such as the GLATT, ACCELACOTA, Vector, Diosna, O'Hara, HICOATER or other such coating process equipment.
  • Seamless minicapsules may be manufactured using the method described in US5, 882,680 (Freund), the entire contents of which are incorporated herein by reference.
  • modified-release formulations are known in the art and are described, for example, in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,566.
  • a number of modified dosage forms suitable for use are described below.
  • modified-release formulations include but are not limited to, membrane-modified, matrix, osmotic, and ion-exchange systems. All of these can be in the form of single-unit or multi-unit dosage forms, as alluded to above.
  • a semi-permeable membrane can surround the formulation containing the active substance of interest.
  • Semi-permeable membranes include those that are permeable to a greater or lesser extent to both water and solute.
  • This membrane can include water-insoluble and/or water-soluble polymers, and can exhibit pH-dependent and/or pH-independent solubility characteristics. Polymers of these types are described in detail below. Generally, the characteristics of the polymeric membrane, which may be determined by, e.g., the composition of the membrane, will determine the nature of release from the dosage form.
  • the present invention provides for formulations of minicapsules or minispheres wherein the modified release is dependent upon, where appropriate, any one of the core formulation constituents, the shell composition or the shell coating.
  • the minicapsules or minispheres may be produced through the utilisation of surface tension of one or more different solutions which when ejected through an orifice or nozzle with a certain diameter and subject to specific frequencies and gravitational flow, forms into a spherical form and falls into a cooling air flow or into a cooling or hardening solution and the outer shell solution where it is gelled or solidified.
  • the core solution is mainly a hydrophobic solution or suspension.
  • the outer shell solution can be any gel forming agent but is normally gelatine- or alginate-based based but may also include polymers or other materials that enable controlled release.
  • a hydrophilic solution can also be encapsulated with the existence of an intermediate solution, which can avoid the direct contact of the hydrophilic core solution with the outer shell.
  • a minicapsule or a bead of shell/core mixed suspension can be processed.
  • a hydrophobic solution can be encapsulated.
  • both the core and / or shell may be comprised of a material or material composites that have been processed by a wet- or dry-extrusion mechanism, melt or otherwise fluidized prior to mixing or extrusion.
  • a wet- or dry-extrusion mechanism melt or otherwise fluidized prior to mixing or extrusion.
  • all processes will result in fairly uniform morphologies with a relatively smooth surface to facilitate quite even coating layers to be added in a uniform manner.
  • seamless minicapsules for various applications can be processed using minicapsule processing equipment enabled by, but not limited to, Freund Spherex, ITAS/Lambo Globex or Inotech processing equipment.
  • the coating process can be carried out by any suitable means, for example, by using a perforated pan or fluidized-baed system such as the GLATT, Vector, ACCELACOTA, Diosna, O'Hara and/or HICOATER processing equipment.
  • a perforated pan or fluidized-baed system such as the GLATT, Vector, ACCELACOTA, Diosna, O'Hara and/or HICOATER processing equipment.
  • the result is modified release compositions that in operation deliver one or more active ingredients in a unique, bimodal or multimodal manner.
  • the present invention further relates to solid oral dosage forms, sachets or other orally deliverable formats containing such multiple minicapsule or minisphere controlled release compositions as well as methods for delivering one or more active ingredients to a patient in a bimodal or multimodal manner.
  • the invention permits targeted release of orally delivered formulations to specific regions of the gastrointestinal tract to maximize absorption, confer protection on the payload, to optimize treatment of diseased intestinal tissue or enhance oral bioavailability.
  • the invention enables one or more pharmaceutical active to be administered sequentially or concomitantly to improve disease treatment and management and to benefit from the body's natural circadian rhythms.
  • the invention also permits the release of pharmaceutical actives into the ileum and colon for the enhanced treatment of local intestinal diseases or to facilitate the absorption of active pharmaceutical agents, including biopharmaceuticals such as peptide and proteins.
  • lipid-based conjugates which confer upon the active agent a more lipid-like nature which permits enhanced small intestinal permeability and hence systemic bioavailability.
  • the potential applications include, but are not limited to, anticancer agents to target metastatic cancerous cells in the lymphatic system, vaccines, immunomodulators, including immunostimulators, agents that undergo extensive first-pass effects in the liver, as well as to enhance the relative half-live of active pharmaceuticals in patients with short bowels and where absorption is limited to the intact small intestine.
  • the invention relates to drug delivery in the colon which has been largely overlooked from a drug delivery perspective.
  • the colon is home to a natural bacterial flora to degrade complex carbohydrates to ensure effective excretion, provide much needed fibre and some nutrient absorption.
  • proteolytic and other enzymes populated in the colon, it is a much more benign environment for proteins and peptides as well as other biological entities such as carbohydrates and nucleic acids.
  • the colon presents a number of interesting possibilities: the bacteria can be harnessed to break down controlled release coatings that are resistant to acidic breakdown as well as pH differentials; the benign environment ensure than active pharmaceuticals, including biopharmaceuticals, are less likely to be degraded if released locally into the colon; the almost continuous flow of fluids from the colonic lumen to the bloodstream may be harnessed to carry hydrophilic entities from the intestine to the lumen. Finally, the long transit time in the colon, ranging form 10-20 hours provides greater residence and potential for interaction with the colonic mucus and epithelial cells leading to enhanced absorption.
  • this invention is based on various modifications of basic one- or multi- layered minicapsules, modulating the core, the shell or the coating to permit enhanced solubility and permeability of the drug or other active or non-active entity as well as conferring protection on drugs or entities that are susceptible to various forms of intestinal, mucosal or systemic degradation and targeted release of the therapeutically- active or -inactive entities to predetermined regions of the gastrointestinal tract.
  • the present invention provides the coating of minicapsules or minispheres with a muco- or bio-adhesive entity which will ensure that they first adhere to the mucosa prior to releasing the fragile payload.
  • the advantages thus enabled include further protection of the active entities but also release of the actives proximal to the site of absorption.
  • absorption is, in part, related to the surface area exposed to the active as well as the concentration gradient from intestinal luminal side to the intestinal basal side, the higher local yet dispersed concentration has greater potential to ensure enhanced absorption, not only of hydrophilic drugs, but also lipophilic or hydrophobic drugs.
  • a barrier to effective colonic delivery of hydrophobic and lipophilic drugs is that the colon did not evolve to solubilize foodstuffs and other entities but rather to ensure electrolyte balance and maximize fibre breakdown and fermentation.
  • the colon remains very porous to hydrophilic entities.
  • hydrophobic or lipophilic drugs to the colon in a pre-solubilised or readily soluble format and releasing such in the colon, the potential for absorption is enhanced significantly.
  • the present invention permits the encapsulation of pre-solubilized or readily soluble drugs in liquid or hydrolysable semisolids or solids into the minicapsule core and then modulation of the shell to include intestinal- or colon-controlled release polymers or coating the shell with same. The result is release of optimized formulations at specific sites along the intestinal tract for maximal therapeutic efficacy or systemic absorption.
  • the formulations of the present invention can exist as multi-unit or single-unit formulations.
  • multi-unit as used herein means a plurality of discrete or aggregated minicapsules, minispheres, particles, beads, pellets, granules, tablets, or mixtures thereof, for example, without regard to their size, shape, or morphology.
  • Single- unit formulations include, for example, tablets, hard gelatin capsules, caplets, and pills.
  • a formulation and/or method of the invention can contain components that exhibit extended-release and immediate-release properties, or both delayed-release and immediate-release properties, or both extended-release and delayed- release properties, or a combination of all three properties.
  • a multi- minicapsule or multi-mini sphere formulation including both immediate-release and extended-release components can be combined in a capsule, which is then coated with an enteric coat to provide a delayed-release effect.
  • a delayed- and extended- release caplet may comprise a plurality of discrete extended-release particles held together with a binder in the caplet, which is coated with an enteric coating to create a delay in dissolution.
  • modified-release formulation or dosage form includes pharmaceutical preparations that achieve a desired release of the drug from the formulation.
  • a modified-release formulation can be designed to modify the manner in which the active ingredient is exposed to the desired target.
  • a modified-release formulation can be designed to focus the delivery of the active agent entirely in the distal large intestine, beginning at the cecum, and continuing through the ascending, transverse, and descending colon, and ending in the sigmoid colon.
  • a modified-release composition can be designed to focus the delivery of the drug in the proximal small intestine, beginning at the duodenum and ending at the ileum.
  • the modified-release formulations can be designed to begin releasing active agent in the jejunum and end their release in the transverse colon or rectum. The possibilities and combinations are numerous, and are clearly not limited to these examples.
  • modified-release encompasses "extended-release” and “delayed-release” formulations, as well as formulations having both extended-release and delayed-release characteristics.
  • An “extended-release” formulation can extend the period over which drug is released or targeted to the desired site.
  • a “delayed-release” formulation can be designed to delay the release of the pharmaceutically active compound for a specified period. Such formulations are referred to herein as “delayed-release” or “delayed-onset” formulations or dosage forms.
  • Modif ⁇ ed-release formulations of the present invention include those that exhibit both a delayed- and extended-release, for example, formulations that only begin releasing after a fixed period of time or after a physicochemical change has occurred, for example, then continue releasing over an extended period.
  • immediate-release formulation is meant to describe those formulations in which more than about 50% of active ingredient is released from the dosage form in less than about 2 hours. Such formulations are also referred to herein as “conventional formulations.”
  • drug-release profile that is independent of surrounding pH means effectively a drug composition comprising a polymeric system that is non-enteric or whose permeability and solubility properties do not change with environmental, i.e., external, pH. Meaning, a drug composition having release characteristics such as dissolution is substantially unaffected by pH or regardless of pH-changes in the environment. This is in comparison to a release profile that is pH-dependent where the release characteristics vary according to the pH of the environment.
  • medium and long-chain fatty acids exert an intestinal epithelial effect which leads to an increased permeability of intestinal membranes to entities that may otherwise be impermeable or exhibit limited permeability.
  • the medium chain triglycerides including but not limited to sodium caprate, enhance absorption to a greater extent in the small intestine than in the ileum or colon (results attached).
  • medium chain triglycerides enhance intestinal permeability while DHA is a possible means of facilitating the intestinal absorption of insulin and possibly other macromolecules, peptides and proteins included, without inducing any serious damage to epithelial cells.
  • Combining poorly permeable entities with medium- or long-chain fatty acids and targeted delivery to local regions of the intestine or colon has the potential to enhance absorption of otherwise poorly permeable entities.
  • the current invention seeks to enable such delivery through the encapsulation of entities formulated with polyunsaturated fatty acids using a gelling agent, including, but not limited to one or a mixture of gelatine, pectin, alginate or chitosan, with or without an additional colon-specific coating.
  • the primary advantage of the current invention relates to enhanced colon delivery for absorption from the colon or treatment of diseased intestinal and colonic tissue
  • the invention also permits the development of sustained absorption of hydrophobic and lipophilic drugs that otherwise would not be soluble in the colon.
  • the invention also facilitates the development of novel combination therapies as well as inventive chronotherapies comprising one or a multiple of drugs released at different time points.
  • Inflammatory bowel diseases which genus encompass a range of diseases including Crohn's disease and ulcerative colitis, affect nearly 1 million people in the United States each year.
  • the two most common inflammatory conditions of the intestine ulcerative colitis (UC) and Crohn's disease (CD), are collectively known as inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • These conditions are diseases of the distal gut (lower small intestine, large intestine, and rectum) rather than the proximal gut (stomach and upper small intestine).
  • ulcerative colitis primarily affects the colon, whereas Crohn's disease affects the distal small intestine as well.
  • Tacrolimus is differentially absorbed from in different regions of the gastrointestinal tract, being optimally absorbed from the small intestine, with ileum and colonic absorption efficiency dropping to half that observed for the small intestine. Also, a food effect is observed. After absorption from the gastrointestinal tract, drug effects persist for 8-12 hours after oral administration of conventional IR tablets. The total dosage is typically in the range of 2.5-10 mg per day, in exceptional cases rising to 20 mg/day. Under conventional dosage regimes, tacrolimus is given twice daily, typically with one dose given before breakfast and a second dose given in the late afternoon.
  • sustained release format either through modifying the core formulation to enable sustained release or coating the surface with a sustained release polymer will reduce the peak plasma drug concentration, thereby reducing the potential dose-related side effects, including nephrotoxicity, neurotoxicity and excessive immunosuppression.
  • IBD Inflammatory Bowel Disease
  • Drugs commonly used in their treatment include steroids (e.g., budesonide and other corticosteroids, and adrenal steroids such as prednisone and hydrocortisone); cytokines such as interleukin-10; antibiotics; immunomodulating agents such as azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and anti-tumor necrosis factor (TNF) agents such as soluble TNF receptor and antibodies raised to TNF; and also antinflammatory agents such as zinc.
  • the most commonly prescribed agents for LBD include sulfasalazine (salicyl-azo-sulfapyridine, or "SASP") and related 5- aminosalicylic acid (“5-ASA”) products, including mesalazine.
  • iletis Inflammation of the ileum (the farthest segment of the small intestine) due to Crohn's disease is known as iletis.
  • Crohn's enterocolitis or ileocolitis.
  • Other descriptive terms may be used as well. Diagnosis is commonly made by x-ray or colonoscopy.
  • Treatment includes medications that are antiinflammatories, immune suppressors, or antibiotics. Surgery can be necessary in severe cases. Crohn's disease is an area of active research around the world and new treatment approaches are being investigated which have promise to improve the lives of affected patients.
  • G-GVHD Gastrointestinal Graft- Versus-Host-Disease
  • Gl GVHD is a life-threatening condition and one of the most common causes for bone marrow and stem cell transplant failure. These procedures are being increasingly used to treat patients with leukemia and other cancers to eliminate residual disease and reduce the likelihood of relapse. Unlike solid organ transplants where the patient's body may reject the organ, in GVHD it is the donor cells that begin to attack the patient's body - most frequently the gut, liver and skin. Patients with mild-to-moderate Gl GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI
  • GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal.
  • Systemic immunosuppressive agents such as prednisone, which are the current standard treatments for GI GVHD, are associated with high mortality rates due to infection and debility. Further, these drugs have not been approved for treating GI GVHD in the U.S. or European Union, but rather are used off-label as investigational therapies for this indication.
  • the current invention permitting colon-targeted release of tacrolimus to the colon, is a novel oral, locally acting active therapy which will reduce the need for systemic immunosuppressive drugs such as prednisone, which is currently used to prevent and control Gl GVHD.
  • Drugs such as prednisone have the unwanted and potentially dangerous side effects of weakening the patient's immune system leaving them susceptible to opportunistic infections as well as substantially inhibiting the intended anticancer effect of bone marrow and stem cell transplants.
  • the colon-targeted tacrolimus therapy is designed to reduce the need for systemic immunosuppressive drugs and thereby improve the outcome of bone marrow and stem cell transplantation.
  • Tacrolimus is recognized, on- and off-label, as common treatments for IBD and is widely used for this purpose.
  • tactolimus therapy may continue to exhibit problems, including side effects to be detailed hereinafter.
  • Extensive tacrolimus absorption from the small intestine reduces its availability at distal sites in the gut. which are the sites of the therapeutic effect and the preferred sites of delivery, thereby necessitating high doses to be administered.
  • the compound should reach the distal gut (ileum and/or colon) in unchanged form, but not be absorbed into the systemic circulation as the parent compound from there.
  • the absorption into the systemic circulation from proximal and/or distal sites as the parent compound results in side effects associated with the absorbed drug and its systemic effects.
  • Existing oral dosage forms of tacrolimus namely soft or hard gelatine capsules, are unsuited to controlled or ileum / colon targeted release.
  • the current invention proposes first formulating tacrolimus as solubilised formulations, encapsulating with a gelling agent to produce minicapsules.
  • the encapsulating agent may contain controlled release polymers that release only in the ileum or colon or may be coated with a polymer or other coating that results in same.
  • the advantages are several- fold, including: reduced systemic absorption of the active tacrolimus which is known to result in dose related toxicities, including nephrotoxicity, release of sufficient dose of tacrolimus in soluble form as well as a broad distribution of tacrolimus throughout the colon.
  • incorporating a mucoadhesive into the encapsulating shell or coating the encapsulating shell with a mucoadhesive may ensure that the minicapsules are in contact with the colonic mucus layer prior to releasing the active proximal to the diseased tissue.
  • a mucoadhesive for certain Crohn's Disease sub-groups it may be required to enable release throughout the gastrointestinal tract, including the small intestine.
  • GI- GVHD it may be beneficial to have sustained release throughout the entire gastrointestinal tract from small intestine to colon.
  • the present invention provides a multiple minicapsule modified release composition comprising at least one population of tacrolimus-containing minicapsules which, upon administration to a patient, exhibits a single, bimodal or multimodal release profile throughout the entire gastrointestinal tract or at pre-specified regions along the gastrointestinal tract.
  • the multiple minicapsule or minisphere modified release composition may comprise at least two populations of tacrolimus-containing minicapsules which, upon administration to a patient, exhibits a bimodal or multimodal release profile that results in a plasma profile within therapeutically effective pharmacokinetic parameters.
  • the invention provides a multiple minicapsule modified release composition comprising at least two populations of tacrolimus-containing minicapsules which, upon administration to a patient, exhibits a pulsatile release profile.
  • the invention provides a multiple minicapsule modified release composition comprising at least two populations of tacrolimus minicapsules which, upon administration to a patient, results in a, pulsatile plasma profile.
  • the invention also provides a multiple minicapsule modified release composition comprising at least two populations of active ingredient-containing minicapsules which, upon administration to a patient, produces a plasma profile substantially similar to the plasma profile produced by the administration of at least dosage forms, one immediate release and the other sustained release given sequentially.
  • the invention provides a multiple minicapsule modified release composition whereby the tacrolimus is released in the ileum or colon, where the active is not absorbed but may yet be locally active.
  • the minicapsule core composition may include excipients in a liquid form that permit controlled or sustained release in conjunction with or independent of the shell or coating.
  • excipients in a liquid form that permit controlled or sustained release in conjunction with or independent of the shell or coating.
  • Such forms can include various temperature modulated lipid-based, wax-like excipients, including, but not limited to the Gattefosse Gelucire® range of saturated triglycerides or the Sasol range of Witepsol® saturated triglycerides which demonstrate considerable sustained release when exposed to the gastrointestinal environment.
  • the minicapsule core composition may include excipients in a semi-liquid or solid form that permit controlled or sustained release in conjunction with or independent of the shell or coating or where the core comprises the entire minicapsule or minisphere.
  • the pharmaceutically acceptable excipient may be chosen from carriers, fillers, extenders, binders, humectants, disintegrating agents, solution-retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, stabilizers, coloring agents, buffering agents, dispersing agents, preservatives, organic acids, and organic bases.
  • the modified-release compositions of the invention may comprise an immediate-release core and a semi-permeable membrane.
  • the modified-release compositions of the invention may comprise a modified-release semi-solid core and a semi-permeable membrane.
  • the present invention also provides sustained release of drugs that otherwise are readily absorbed in the small intestine but exhibit limited colonic absorption is made possible through targeted release of formulations wherein the drug or other entity is pre- solubilised.
  • An example of such drugs includes tacrolimus.
  • the present invention also permits development of sustained release tacrolimus in combination with an antioxidant or nuclear factor kappa B inhibitor such as, but not limited to curcuminoids, such as, but not limited to curcumin, to reduce nephrotoxicity or increase effectiveness in treating inflammatory bowel disease or to enhance efficacy in the treatment of diabetes-related kidney disorders.
  • an antioxidant or nuclear factor kappa B inhibitor such as, but not limited to curcuminoids, such as, but not limited to curcumin
  • the present invention also permits development of sustained release tacrolimus, sirolimus, cyclosporine or derivatives thereof in combination with mycophenolate motefil and / or other immunomodulators to enhance the management of post-transplant treatment.
  • the invention also includes methods of treating inflammatory bowel disease comprising administering to a subject in need thereof a pharmaceutical composition comprising a dose of tacrolimus, or pharmaceutically acceptable salts, esters and pro-drugs thereof, and at least one pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising a dose of tacrolimus, or pharmaceutically acceptable salts, esters and pro-drugs thereof, and at least one pharmaceutically acceptable excipient.
  • Such formulations are preferentially developed to ensure release in the ileum and / or colon.
  • Still another embodiment of this invention relates to methods of treating inflammatory bowel disease comprising administering to a subject in need thereof a pharmaceutical composition comprising tacrolimus and a curcuminoid, such as, but not limited to, curcumin, with release of same targeted to the ileum or colon.
  • a pharmaceutical composition comprising tacrolimus and a curcuminoid, such as, but not limited to, curcumin, with release of same targeted to the ileum or colon.
  • Another embodiment of the present invention relates to development of sustained release tacrolimus in combination with the delivery of natural plant, marine or other extracts, including essential oils such as Neem, aloe vera and the omega range of polyunsaturated oils, including EPA, DHA and CLA, with or without plant extracts such as, but not limited to, berry extracts, tripala, tumeric, resveratrol, resorcinolic/phenolic lipids, flavanoids and any natural or synthetic derivatives thereof.
  • essential oils such as Neem, aloe vera and the omega range of polyunsaturated oils, including EPA, DHA and CLA
  • plant extracts such as, but not limited to, berry extracts, tripala, tumeric, resveratrol, resorcinolic/phenolic lipids, flavanoids and any natural or synthetic derivatives thereof.
  • Another embodiment of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of any of the above examples released anywhere along the gastrointestinal tract.
  • Another embodiment of the current invention relates to non-covalent complexion of a drug with a carrier such as cyclodextrins, maltodextrins, dextrins or modifications thereof and targeting the release of such to the specific sites along the gastrointestinal tract.
  • a carrier such as cyclodextrins, maltodextrins, dextrins or modifications thereof
  • Yet a further embodiment of the present invention is targeted gastrointestinal release of formulations containing conjugated drugs, the conjugation which prevents absorption into the systemic or lymphatic vasculature yet retains local intestinal therapeutic efficacy.
  • Still a further embodiment of the present invention is targeted gastrointestinal release of formulations comprising poorly soluble actives, including small molecules and biopharmaceuticals formulated with amongst other excipients, permeability enhancers, such as, but not limited to, sodium dodecanoate (C 12), Sodium Caprate (ClO) and / or Sodium Palmitate (C 16).
  • poorly soluble actives including small molecules and biopharmaceuticals formulated with amongst other excipients, permeability enhancers, such as, but not limited to, sodium dodecanoate (C 12), Sodium Caprate (ClO) and / or Sodium Palmitate (C 16).
  • the active pharmaceutical ingredient is interchangeable, including any one or combination of tacrolimus with any one of EPA, DHA, natural plant extracts, natural marine extracts or other biological and active entities, which may include siRNA constructs.
  • the active pharmaceutical ingredient is interchangeable, including any one or combination of tacrolimus with any one of EPA, DHA, natural plant extracts, natural marine extracts or other biological and active entities, which may include siRNA constructs.
  • the active pharmaceutical ingredient is interchangeable, including any one or combination of tacrolimus with any one of EPA, DHA, natural plant extracts, natural marine extracts or other biological and active entities, which may include siRNA constructs.
  • the immunological modulating entities including antigens. adjuvants, emulsions, oils, and small molecules are interchangeable and may be utilised for the development of vaccines, oral tolerance modulators and allergen modulators, which may include siRNA constructs.
  • the invention allows for the development of solid-, semi-solid or liquid-filled minicapsules comprising one or more layer and produced using conventional seamless minicapsule processes, modified melt extrusion, non-pareil coating, non-pareil drug layering or other processes that enable the production of the desired dosage form.
  • the invention provides a solid oral. dosage form comprising the multiple minicapsule modified release composition of the present invention, the said minicapsules being one layer or multiple layers.
  • a two layer minicapsule has a shell comprised of a gelling agent with a controlled release polymer or other coating or comprised of controlled release polymer or other materials.
  • the invention also provides a sachet format comprising multiple minicapsule modified release composition of the present invention for ease of administration to paediatrics, geriatrics or other patient populations with swallowing difficulties.
  • FIG. 7 illustrates liquid-filled minicapsule with controlled release polymer coatings.
  • This format comprises an active substance L encapsulated using a suitable gelling agent C that may be further coated to permit controlled or targeted release along the gastrointestinal tract.
  • the active substance is in an enhanced solubilised or permeabilised form.
  • the open arrow represents the release of a drug molecule M into the external medium, where it is fully soluble when released;
  • the core formulation was prepared as follows. Tacrolimus was dissolved in a suitable volume of ethanol. Once dissolved, the solution was blended with a suitable mix of Labrafil and Olive oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises Tacrolimus in an enhanced solubilised and permeabilised formulation. In addition, the core formulation does enable a degree of sustained release.
  • Figure 1 demonstrate the following release of tacolimus from minicapsules expressed as a percentage of the total minicapsule content: less than 55% within lhr; less than 80% within 4hrs; less than 90% within 12hrs and less than or equal to 100% at 24hr.
  • Example 3 Tacrolimus release from minicapsules of Example 1 coated with 12.5% weight gain EudragitTM RS30D followed by 25% weight gain EudragitTM FS30D: Dissolution profiles in Figure 2 demonstrate the following release of tacolimus from minicapsules expressed as a percentage of the total minicapsule content: less than 10% within lhr; less than 30% within 4hrs; less than 75% within 12hrs and less than or equal to 100% at 24hr. This is suited either to a once-daily systemic absorption product or an ileum/colon-specific product.
  • Tacrolimus release from minicapsules of Example 1 coated with 15% weight gain EudragitTM RS30D Dissolution profiles in Figure 4 demonstrate the following release of tacolimus from minicapsules expressed as a percentage of the total minicapsule content: less than 30% within lhr; less than 50% within 4hrs; less than 85% within 12hrs and less than or equal to 100% at 24hr.
  • Dissolution profiles in Figure 6 demonstrate the following release of tacolimus from minicapsules expressed as a percentage of the total minicapsule content: greater than 20% and less than 50% within lhr; greater than 35% and less than 60% within 4hrs; greater than 65% and less than 90% within 12hrs and greater than 90% at 24hr.
  • the core formulation was prepared as follows: Tacrolimus was added to a suitable volume Gelcuire 33/01 heated and stirred until dissolved. Once dissolved, the solution was blended with a suitable volume of Olive oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises Tacrolimus in an enhanced solubilised and permeable formulation.
  • the core formulation is inherently sustained release.
  • the sustained release coating comprises a 95:5 ratio of EudragitTM RS: EudragitTM RL.
  • the combination comprises 95:5 EudragitTM RS:RL, further coated with Eudragit FS30D.
  • the core formulation was prepared as follows: Tacrolimus was added to a suitable volume Gelcuire 44/01 heated and stirred until dissolved. Once dissolved, the solution was blended with a suitable volume of Fish oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, ; ; the core of which comprises Tacrolimus in an enhanced solubi ⁇ sed and permeable > formulation.
  • the core formulation is inherently sustained release.
  • Tacrolimus is released from uncoat ⁇ d minicapsules as follows: 50% released within 4 hours; 100% within 12 hours. To enable a once-daily product, the minicapsules will be coated either with a sustained release polymer or a combination of colonic-specific polymer and sustained release polymers.
  • the sustained release coating comprises Surelease®, with or without the inclusion of high or low molecular weight pectin in the coating solution and with or without further coating the mincapsules with the pH sensitive EudragitTM FS30D.
  • Example 10 Ileum- and Colon-specific Tacrolimus
  • the core formulation was prepared as follows. Tacrolimus was dissolved in a suitable volume of ethanol. Once dissolved, the solution was blended with a suitable mix of Labrafil and Olive oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises tacrolimus in an enhanced solubilised and permeabilised formulation.
  • the core formulation does include the addition of ileum and / or colon specific release polymer coatings to enable a degree of targeted and / or release.
  • the minicapsules are coated either with a sustained release polymer or a combination of colonic-specific polymer and sustained release polymers.
  • the sustained release coating comprises minicapsules coated with 12.5% weight gain EudragitTM RS30D followed by 25% weight gain EudragitTM FS30D.
  • Example 11 Ileum- and Colon-specific Tacrolimus
  • the core formulation was prepared as follows. Tacrolimus was dissolved in a suitable volume of ethanol. Once dissolved, the solution was blended with a suitable mix of Labrafil and Neem oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises tacrolimus in an enhanced solubilised and permeabilised formulation. In addition, the core formulation does enable a degree of sustained release.
  • the minicapsules can be coated either with a sustained release polymer or a combination of colonic-specific polymer and sustained release polymers.
  • Example 12 Ileum- and Colon-specific Tacrolimus
  • the core formulation was prepared as follows. Tacrolimus was dissolved in a suitable volume of ethanol. Once dissolved, the solution was blended with a suitable mix of Labrafil and Fish oil.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises tacrolimus in an enhanced solubilised and permeabilised formulation. In addition, the core formulation does enable a degree of sustained release.
  • the minicapsules can be coated either with a sustained release polymer as a combination of Surelease® and USP Pectin in a 2:1 w/w ratio with a 30% weight gain.
  • Example 13 Ileum- and Colon-specific Tacrolimus
  • the core formulation was prepared as follows. Polyethylene glycol 400, Glyceryl Monooleate and Decaglyceryl monooleate were mixed together at 50 degrees C until in solution. Tacrolimus together with the propylene glycol and tocopherol linoleate where added and the mixture stirred under an inert gas blanket until dissolved.
  • the shell solution was prepared as follows: Appropriate quantities of gelatin and sorbitol were added to water and heated to 70 degrees C until in solution.
  • the minicapsules were prepared using a Spherex Labo to produce 2-layer minicapsules, the core of which comprises tacrolimus in an enhanced solubilised and permeabilised formulation. In addition, the core formulation does enable a degree of sustained release.
  • the minicapsules can be coated either with a sustained release polymer as a combination of Surelease® and USP Pectin in a 2:1 w/w ratio with a 30% weight gain.
  • EudragitTM RS - Tacrolimus containing minicapsules were coated with EudragitTM RS with or without further coating with EudragitTM FS30D.
  • Surelease® - Tacrolimus containing minicapsules were coated with Surelease® with or without further coating with EudragitTM FS30D.
  • Surelease® and Pectin - Tacrolimus containing minicapsules were coated with Surelease®, with or without the inclusion of high or low molecular weight pectin in the coating solution and with or without further coating the mincapsules with the pH sensitive EudragitTM FS30D.
  • Surelease® and Alginate - Tacrolimus containing minicapsules were coated with Surelease®, with or without the inclusion of alginate in the coating solution and with or without further coating the mincapsules with the pH sensitive EudragitTM FS30D.
  • the sustained release coating may comprise a combination of Surelease® and USP Pectin in a 2:1 w/w ratio with a 30% weight gain.
  • the sustained release coating may comprise EudragitTM RS with a weight gain of 22%.
  • the once-daily formulation will typically comprise a blend of uncoated and coated minicapsules to provide 0-50% release between 6 and 12 hours and 0-100% release between 12 and 24 hours.
  • the invention envisages the use of a tacrolimus fo ⁇ nulation in combination -with another therapeutically or propylactically active entity or entities, as single fixed combination dosage form or to be administered separately.
  • immunosuppressants could be considered, either alone or in combination with tacrolimus or derivatives thereof.
  • these include, but are not limited to, various other calcineurin inhibitors such as but not limited to Abetimus, Deforolimus, Everolimus, Gusperimus, Pimecrolimus, Sirolimus, Cyclosporins, Temsirolimus; glucocorticosteriods such as but not limited to Cortisone, Hydrocortisone, Fludrocortisone, Prednisone, Prenisolone, Methylpredilisolone, Triamcinolone, Betamethasone, Dexamethasone or Paramethasone ; cytostatics such as but not limited to Anakinra, Azathioprine, Leflunomide, Methotrexate, Mycophenolic acid, Thalidomide; antibodies such as the T-cell receptor directed anti-CD3 OKT3; the immunophilin receptor binder si
  • infliximab etanercept, adalimumab, cucumin and catechins
  • Mycophenolate Mofetil acid which acts as a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase.
  • the above list include derivatives thereof, including those modified to include a conjugated NO donor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
PCT/IE2008/000039 2007-04-04 2008-04-04 A pharmaceutical composition of tacrolimus Ceased WO2008122966A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/594,553 US8911777B2 (en) 2007-04-04 2008-04-04 Pharmaceutical composition of tacrolimus
CA002683409A CA2683409A1 (en) 2007-04-04 2008-04-04 A pharmaceutical composition of tacrolimus
EP08719897A EP2061440A2 (en) 2007-04-04 2008-04-04 A pharmaceutical composition of tacrolimus
JP2010501661A JP2010523554A (ja) 2007-04-04 2008-04-04 タクロリムスの医薬組成物
CN200880016191A CN101677964A (zh) 2007-04-04 2008-04-04 他克莫司药物组合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90749007P 2007-04-04 2007-04-04
US60/907,490 2007-04-04
US649808P 2008-01-16 2008-01-16
US61/006,498 2008-01-16

Publications (2)

Publication Number Publication Date
WO2008122966A2 true WO2008122966A2 (en) 2008-10-16
WO2008122966A3 WO2008122966A3 (en) 2008-12-24

Family

ID=39745242

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IE2008/000039 Ceased WO2008122966A2 (en) 2007-04-04 2008-04-04 A pharmaceutical composition of tacrolimus
PCT/IE2008/000038 Ceased WO2008122965A2 (en) 2007-04-04 2008-04-04 Pharmaceutical cyclosporin compositions
PCT/IE2008/000040 Ceased WO2008122967A2 (en) 2007-04-04 2008-04-04 An oral pharmaceutical composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IE2008/000038 Ceased WO2008122965A2 (en) 2007-04-04 2008-04-04 Pharmaceutical cyclosporin compositions
PCT/IE2008/000040 Ceased WO2008122967A2 (en) 2007-04-04 2008-04-04 An oral pharmaceutical composition

Country Status (11)

Country Link
US (11) US8911777B2 (enExample)
EP (5) EP2380564B1 (enExample)
JP (6) JP2010523555A (enExample)
CN (6) CN101677964A (enExample)
CA (3) CA2683409A1 (enExample)
CY (1) CY1113882T1 (enExample)
DK (1) DK2079456T3 (enExample)
ES (3) ES2524345T3 (enExample)
HR (1) HRP20130173T1 (enExample)
PT (1) PT2079456E (enExample)
WO (3) WO2008122966A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434139B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Oral pharmaceutical composition
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
US11230567B2 (en) 2014-09-02 2022-01-25 Purecircle Usa Inc. Stevia extracts enriched in rebaudioside D, E, N and/or O and process for the preparation thereof
WO2022109684A1 (en) * 2020-11-30 2022-06-02 Royal Melbourne Institute Of Technology Oral therapeutic delivery
US12042562B2 (en) 2015-06-03 2024-07-23 Triastek, Inc. 3D printing methods for compartmented pharmaceutical dosage forms
US12102721B2 (en) 2017-01-26 2024-10-01 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2922402B2 (ja) 1993-10-14 1999-07-26 住友重機械工業株式会社 熱成形方法及びその熱成形装置
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
RS56049B1 (sr) * 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
CN105213318A (zh) 2009-05-18 2016-01-06 希格默伊德药业有限公司 包含油滴的组合物
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX2021000431A (es) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2868990C (en) 2011-04-22 2018-08-14 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US9561241B1 (en) * 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
CA3008794C (en) * 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
BR112014027496A2 (pt) * 2012-05-04 2018-05-15 Univ Chicago biodisponibilidade de metilnaltrexona oral aumenta com uma formulação à base de fosfatidilcolina
DE102012105528A1 (de) * 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP5992247B2 (ja) * 2012-08-13 2016-09-14 国立大学法人大阪大学 核酸医薬経口製剤
JP6062802B2 (ja) * 2012-08-23 2017-01-18 日清ファルマ株式会社 キトサン含有組成物及びキトサンコーティング組成物
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
EP2968329A4 (en) * 2013-03-15 2016-09-28 Galleon Pharmaceuticals Inc NEW BREATHING CONTROL MODULATION COMPOUNDS AND METHODS OF USING THE SAME
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
US9415110B1 (en) 2013-05-08 2016-08-16 The Arizona Board of Regents on behalf of the Univeristy of Arizona Method and compositions for targeted drug delivery to the lower GI tract
CN104127466B (zh) * 2013-08-23 2018-05-22 江苏省中医药研究院 一种淫羊藿总黄酮口服肠溶制剂及其应用
CN104548063A (zh) * 2013-10-29 2015-04-29 中国科学院上海有机化学研究所 一种免疫抑制剂在制备线粒体丝氨酸/苏氨酸蛋白磷酸酶抑制剂中的用途
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
HUP1300647A2 (hu) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
JP6671360B2 (ja) * 2014-06-30 2020-03-25 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法
EP3164145A4 (en) 2014-07-01 2018-01-17 Probi Usa, Inc. Bi-layer dual release probiotic tablets
AU2015299105B2 (en) * 2014-08-04 2020-10-29 Dbv Technologies Compositions of food allergens
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
CN104224732B (zh) * 2014-09-29 2017-06-30 江苏大学 一种口服骨架型环孢素a缓释微丸制剂及其制备方法
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CN113546036A (zh) 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
US10286009B2 (en) * 2015-05-16 2019-05-14 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
EP3435982A1 (en) * 2016-03-31 2019-02-06 VHsquared Limited Compositions
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
TR201610597A2 (tr) * 2016-07-29 2016-12-21 Kamil Varlik Erel Mide ve bağırsak içine yerleştirilen tüp veya sondalardan kullanıma uygun ilaç
NZ751668A (en) * 2016-08-17 2022-07-29 Entera Bio Ltd Formulations for oral administration of active agents
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3046023A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
JP7150723B2 (ja) * 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のインテグリン阻害薬による治療
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018112232A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2018183934A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018231619A1 (en) * 2017-06-14 2018-12-20 SpecGx LLC Delayed sustained release pharmaceutical compositions
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
CN111225686A (zh) * 2017-08-15 2020-06-02 普罗根尼蒂公司 使用可摄入装置释放免疫调节剂治疗炎性疾病
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
AU2018351502B2 (en) * 2017-10-20 2024-09-05 Purdue Pharma L.P. Pharmaceutical dosage forms
CA3085330A1 (en) * 2017-12-14 2019-06-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
US12005086B2 (en) 2018-02-23 2024-06-11 Finch Therapeutics Holdings Llc Microbiome related immunotherapies
AU2019232145B2 (en) * 2018-03-07 2024-08-08 Teagasc - The Agriculture And Food Development Authority A composition for type II diabetics and for use in providing sustained energy release over time
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
WO2019183109A1 (en) * 2018-03-19 2019-09-26 Gemini Laboratories, Llc Immunosuppressive dosage forms and methods of use
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
EP4438618A3 (en) 2018-08-22 2025-01-01 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
CN110934831B (zh) * 2018-09-25 2021-09-14 天津大学 二甲基乙二酰甘氨酸-白藜芦醇核壳型纳米材料及其制备方法
US11839605B2 (en) * 2018-10-11 2023-12-12 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
EP4588511A3 (en) 2019-07-18 2025-07-30 Theriva Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
WO2021030474A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
US20220331378A1 (en) 2019-09-13 2022-10-20 Finch Therapeutics Holdings Llc Compositions and methods for treating autism spectrum disorder
CN115279382A (zh) 2019-10-18 2022-11-01 芬奇治疗控股有限责任公司 用于向受试者递送细菌代谢物的组合物和方法
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN111297953A (zh) * 2019-12-20 2020-06-19 卓和药业集团有限公司 一种预防肾脏移植后移植排斥反应的复方制剂
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
US20230149295A1 (en) * 2020-03-09 2023-05-18 University Of Houston System Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
AU2021377219A1 (en) 2020-11-10 2023-06-29 Medregen, Llc Formulations, methods, kits, and dosage forms
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
AU2022345789A1 (en) * 2021-09-14 2024-03-28 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus
KR102874663B1 (ko) * 2021-12-22 2025-10-23 알고케어 주식회사 구 형상의 제형을 제공하는 디스펜서
CN114916591A (zh) * 2022-06-09 2022-08-19 江西维尔宝食品生物有限公司 一种起酥性烘焙专用可塑性粉末油脂组合物
US11806430B1 (en) 2023-02-24 2023-11-07 King Faisal University Rectal gel with date palm phenolics and vanillic acid
AU2024252387A1 (en) * 2023-04-14 2025-10-02 Vitakey Inc. Compositions and methods of controlling mammalian satiety
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3971852A (en) 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1090703B (it) 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4279632A (en) * 1979-05-08 1981-07-21 Nasa Method and apparatus for producing concentric hollow spheres
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS6415Y2 (enExample) 1981-05-29 1989-01-05
DE3224619A1 (de) * 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JPS5813508A (ja) 1981-07-14 1983-01-26 Taiho Yakuhin Kogyo Kk ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物
JPS5877810A (ja) 1981-11-01 1983-05-11 Taiho Yakuhin Kogyo Kk ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物
US4481157A (en) * 1982-04-27 1984-11-06 Morishita Jintan Co., Ltd. Method and apparatus for production of microcapsules
US4597959A (en) 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
US4422985A (en) * 1982-09-24 1983-12-27 Morishita Jintan Co., Ltd. Method and apparatus for encapsulation of a liquid or meltable solid material
JPS5988420A (ja) 1982-11-12 1984-05-22 Teisan Seiyaku Kk シ−ムレスカプセル化ニフエジピン製剤
JPS5988420U (ja) 1982-12-04 1984-06-15 有限会社三和ボタン店 学生服の詰襟構造
JPS59131355A (ja) * 1983-01-17 1984-07-28 森下仁丹株式会社 多重軟カプセルの製法
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS6115A (ja) 1984-06-12 1986-01-06 Kyowa Hakko Kogyo Co Ltd リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61115462A (ja) 1984-11-13 1986-06-03 Denka Seiyaku Kk 甘味増強ステビア葉の製法
JPS61151119A (ja) 1984-12-24 1986-07-09 Taisho Pharmaceut Co Ltd ソフトカプセル
US4601894A (en) 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4658441A (en) * 1985-12-13 1987-04-21 Smith Steven A One piece thumb support and protector
EP0241806A1 (en) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
JPS6415A (en) 1988-03-17 1989-01-05 Freunt Ind Co Ltd Absorption-improving drug preparation
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2806564B2 (ja) * 1989-07-20 1998-09-30 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
BE1003677A3 (nl) 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE103806T1 (de) * 1990-07-04 1994-04-15 Shionogi & Co Verfahren zur herstellung einer nichtkohaesiven ueberzugsschicht.
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
SG48815A1 (en) 1991-06-28 1998-05-18 Univ Brown Res Found Capsule extrusion systems
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
JPH0549899A (ja) 1991-08-09 1993-03-02 Japan Tobacco Inc ビーズ及びこれを製造するための液滴生成装置
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU666895B2 (en) 1991-12-30 1996-02-29 Hercules Incorporated High load spray dry encapsulation
AU3343093A (en) 1992-01-17 1993-08-03 Alfatec-Pharma Gmbh Pellets containing peptide drugs, their manufacture and use
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
EP0573978B1 (en) * 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
JP3405746B2 (ja) * 1992-10-28 2003-05-12 フロイント産業株式会社 シームレスカプセルの製造方法
DE69332031T2 (de) 1993-01-08 2002-12-19 Csl Ltd., Parkville Impfstoffpräparate
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
CN1077800C (zh) * 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
FR2707184B1 (fr) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4332041C2 (de) 1993-09-21 1997-12-11 Rentschler Arzneimittel Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995022343A1 (en) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
US5498439A (en) 1994-03-04 1996-03-12 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP3867171B2 (ja) 1994-04-22 2007-01-10 アステラス製薬株式会社 結腸特異的薬物放出システム
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5595757A (en) 1995-03-29 1997-01-21 Warner-Lambert Company Seamless capsules
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
JP2682818B2 (ja) 1995-08-04 1997-11-26 大成化工株式会社 害虫誘引阻止材
ATE263550T1 (de) 1995-08-25 2004-04-15 Sangstat Medical Corp Orale cyclosporinformulierungen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
JP3759986B2 (ja) * 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
KR0183449B1 (ko) * 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2283780A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
CA2288876A1 (en) 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
JP4102459B2 (ja) * 1997-05-14 2008-06-18 森下仁丹株式会社 生体高分子を合成するシームレスカプセルおよびその製造方法
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
PT999826E (pt) 1997-07-29 2004-09-30 Upjohn Co Formulacao auto-emulsionante para compostos lipofilos
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3090198B2 (ja) 1997-08-21 2000-09-18 日本電気株式会社 半導体装置の構造およびその製造方法
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
KR100569319B1 (ko) 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1296585B1 (it) 1997-11-28 1999-07-14 Uni Di Pavia Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US6174466B1 (en) * 1998-05-08 2001-01-16 Warner-Lambert Company Methods for making seamless capsules
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
JPH11322587A (ja) * 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
JP3039863B1 (ja) * 1998-12-25 2000-05-08 不二精工株式会社 ロッキングプレス装置
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2000302654A (ja) 1999-04-16 2000-10-31 Kao Corp 歯磨組成物の製造法
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
WO2000069420A1 (en) 1999-05-14 2000-11-23 Coraltis Ltd. Pulse-delivery oral compositions
EP1184038B1 (en) 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2391707C (en) 1999-07-30 2010-05-11 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
WO2001032142A1 (en) 1999-11-02 2001-05-10 Cipla Limited Cyclosporin formulation
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504264A (ja) * 2000-01-07 2004-02-12 ユニバーシティ　オブ　シンシナティ Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
DE60112073T2 (de) 2000-05-12 2006-04-20 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CA2441007C (en) 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
WO2003053404A1 (en) 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
DE60213471T2 (de) 2002-01-10 2007-08-23 Firmenich S.A. Prozess zur herstellung extrudierter abgabesysteme
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
JP4226846B2 (ja) * 2002-06-07 2009-02-18 キャタレント・ジャパン株式会社 口腔内で崩壊可能なソフトカプセル剤
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2408729A (en) 2002-09-04 2005-06-08 Southwest Res Inst Microencapsulation of oxygen or water sensitive materials
KR20120038546A (ko) 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004064997A1 (en) 2003-01-23 2004-08-05 Inotech Ag New microcapsules useful as extraction means in particular for extracting water or soil contaminants
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP2359817B1 (en) 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
CA2521051C (en) * 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
BRPI0414000B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
ES2373937T3 (es) * 2003-11-21 2012-02-10 Commonwealth Scientific And Industrial Research Organisation Sistemas gastro-intestinales de administración.
WO2005072088A2 (en) 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof
CN1268325C (zh) 2004-01-18 2006-08-09 浙江大学 三重复合微球制剂及其制备方法
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
FR2867395B1 (fr) 2004-03-15 2006-06-16 Rhodia Chimie Sa Emulsion sechee, son procede de preparation, et ses utilisations
EP1576881A1 (en) * 2004-03-15 2005-09-21 Urea Casale S.A. Process for the production of granules or pellets containing filamentary fungi
DK1746980T3 (da) 2004-05-07 2012-01-30 Nycomed Gmbh Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
IE20050639A1 (en) * 2004-09-27 2006-09-06 Sigmoid Biotechnologies Ltd Minicapsule formulations
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
CN101212953A (zh) * 2005-03-29 2008-07-02 麦克内尔-Ppc股份有限公司 具有疏水介质中的亲水药物的组合物
US7825087B2 (en) 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
TW200800305A (en) 2005-07-26 2008-01-01 Glaxo Group Ltd Encapsulation of lipid-based formulations in enteric polymers
WO2007014445A1 (en) 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
BRPI0707616A2 (pt) 2006-02-09 2011-05-10 Alba Therapuetics Corp formulaÇÕes para um efetor de junÇço oclusiva
US20070274932A1 (en) * 2006-05-15 2007-11-29 The Procter & Gamble Company Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
EP2380564B1 (en) 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
CA2685591A1 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434139B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Oral pharmaceutical composition
US11230567B2 (en) 2014-09-02 2022-01-25 Purecircle Usa Inc. Stevia extracts enriched in rebaudioside D, E, N and/or O and process for the preparation thereof
US11856972B2 (en) 2014-09-02 2024-01-02 Purecircle Sdn Bhd Stevia extracts
US12295391B2 (en) 2014-09-02 2025-05-13 Purecircle Usa Inc. Stevia extracts enriched in rebaudioside D, E, N and/or O and process for the preparation thereof
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
US12042562B2 (en) 2015-06-03 2024-07-23 Triastek, Inc. 3D printing methods for compartmented pharmaceutical dosage forms
US12324856B2 (en) 2015-06-03 2025-06-10 Triastek, Inc. Oral drug dosage form comprising drug in the form of nanoparticles
US12102721B2 (en) 2017-01-26 2024-10-01 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2022109684A1 (en) * 2020-11-30 2022-06-02 Royal Melbourne Institute Of Technology Oral therapeutic delivery

Also Published As

Publication number Publication date
CN101686948B (zh) 2013-06-19
DK2079456T3 (da) 2013-03-18
ES2524345T3 (es) 2014-12-05
CN103316326A (zh) 2013-09-25
HRP20130173T1 (hr) 2013-04-30
WO2008122967A3 (en) 2008-12-24
CN103120653A (zh) 2013-05-29
EP2066309B1 (en) 2012-08-29
JP2010523554A (ja) 2010-07-15
US20160166635A1 (en) 2016-06-16
CA2683409A1 (en) 2008-10-16
JP2016074686A (ja) 2016-05-12
EP2079456B1 (en) 2012-12-05
JP2017160241A (ja) 2017-09-14
CA2683415C (en) 2020-12-08
US10434139B2 (en) 2019-10-08
EP2409691A1 (en) 2012-01-25
EP2066309A2 (en) 2009-06-10
US10434140B2 (en) 2019-10-08
US9585844B2 (en) 2017-03-07
US20200009218A1 (en) 2020-01-09
US9675558B2 (en) 2017-06-13
CA2683415A1 (en) 2008-10-16
EP2380564A3 (en) 2012-11-14
US20170246242A1 (en) 2017-08-31
CN103316326B (zh) 2016-06-15
WO2008122965A2 (en) 2008-10-16
EP2079456A2 (en) 2009-07-22
EP2380564B1 (en) 2014-10-22
US20170196934A1 (en) 2017-07-13
WO2008122965A3 (en) 2008-12-24
CN103120653B (zh) 2015-09-30
CA2683407C (en) 2016-09-20
US20150374638A1 (en) 2015-12-31
CN105030729A (zh) 2015-11-11
US8911777B2 (en) 2014-12-16
EP2061440A2 (en) 2009-05-27
JP6149090B2 (ja) 2017-06-14
US20130330411A1 (en) 2013-12-12
US20100297221A1 (en) 2010-11-25
CN101686948A (zh) 2010-03-31
ES2400964T3 (es) 2013-04-15
US20200009219A1 (en) 2020-01-09
EP2380564A2 (en) 2011-10-26
CY1113882T1 (el) 2016-07-27
US9387179B2 (en) 2016-07-12
JP2014196368A (ja) 2014-10-16
ES2393814T3 (es) 2012-12-28
US20120258167A1 (en) 2012-10-11
US8535713B2 (en) 2013-09-17
JP6059688B2 (ja) 2017-01-11
US9844513B2 (en) 2017-12-19
US9114071B2 (en) 2015-08-25
WO2008122966A3 (en) 2008-12-24
PT2079456E (pt) 2013-03-13
JP5553747B2 (ja) 2014-07-16
US20100203120A1 (en) 2010-08-12
CA2683407A1 (en) 2008-10-16
WO2008122967A2 (en) 2008-10-16
US20100255087A1 (en) 2010-10-07
CN101677964A (zh) 2010-03-24
CN101990429A (zh) 2011-03-23
JP2010523555A (ja) 2010-07-15
JP2010523553A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
US8911777B2 (en) Pharmaceutical composition of tacrolimus
JP2006521366A (ja) シームレスマイクロカプセルを含む固形経口剤形
WO2009047799A1 (en) High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same
AU2008288106A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
IE20080259A1 (en) A pharmaceutical composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880016191.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719897

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008719897

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2683409

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010501661

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6471/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12594553

Country of ref document: US